fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

INVIMA Confirms Johnson & Johnson’s One Shot Covid-19 Vaccine Shot Receives Approval For Emergency Use In Columbia

By John F. Heerdink, Jr.

Reportedly, Colombia has approved the emergency use of Johnson & Johnson’s (JNJ) one-shot COVID-19 vaccine, informed the director of food and drug regulator INVIMA. The government has entered an agreement to buy 9 million doses of J&J’s one-shot vaccine.

“In its capacity as regulator, INVIMA has authorized the emergency use of the vaccine from the pharmaceutical company Janssen, of the multinational Johnson & Johnson,” stated INVIMA director Julio Cesar Aldana said during the government’s nightly broadcast.

Colombia has also reached agreements for vaccines developed by Pfizer Inc and BioNTech, AstraZeneca, Moderna, and Sinovac. It will further receive doses via the World Health Organization-backed COVAX mechanism.

Colombia has so-far approved the use of the vaccines developed by AstraZeneca and Sinovac, and Pfizer and BioNTech.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 


Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

Post View Count : 176
(Read Original Story: Colombia grants emergency use for J&J coronavirus vaccine in Reuters)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us